Flash talks on immunodeficiencies and autoimmunity

Flash talks on immunodeficiencies and autoimmunity

Comorbidities in Angioedema due to C1-inhibitor deficiency: an Italian survey

Immunoglobulin replacement therapy: unexpected preference for intravenous route in a Portuguese adult cohort

Initial Results from a Phase 1 Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema (HAE), in Healthy Subjects Followed for at Least 3 Months

Long-Term Effectiveness and Safety of Lanadelumab Regardless of Baseline Attack Rate: Pooled Analysis of the ENABLE and EMPOWER Studies

Real-World Effectiveness and Safety of Lanadelumab for Prophylaxis of Hereditary Angioedema Attacks: 2-Year Interim Results From the ENABLE Study

Relationship Between Autoimmune Manifestations and Genetic Disorders in Patients with PID: A Single Center 10-Year Experience

Results From a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial Evaluating Sebetralstat Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability in Healthy Japanese, Chinese, and White Adults

Design of ALPHA-STAR, a Phase 1b/2 Proof-of-Concept Trial of STAR-0215 as a Long-Active Preventative Therapy in Patients with Hereditary Angioedema (HAE) Types I or

GASTROINTESTINAL SYSTEM INVOLVEMENT in PATIENTS WITH PRIMARY IMMUNE DEFICIENCY